Research programme: biodefence vaccines - AlphaVax

Drug Profile

Research programme: biodefence vaccines - AlphaVax

Alternative Names: Biodefense vaccines - AlphaVax; Botulinum toxin vaccine - AlphaVax; Ebola virus vaccine - AlphaVax; Equine encephalomyelitis virus vaccine - AlphaVax; Marburg virus vaccine - AlphaVax; Smallpox virus vaccine - AlphaVax; Venezuelan/Eastern/Western Equine Encephalitis virus vaccine - AlphaVax

Latest Information Update: 08 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AlphaVax
  • Class Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Botulism; Smallpox
  • No development reported Encephalitis virus infections; Marburg virus disease

Most Recent Events

  • 08 Dec 2017 Preclinical development is ongoing for Smallpox and Botulism in USA (AlphaVax pipeline, December 2017)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Botulism in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Encephalitis-virus-infections in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top